Ingevity Corp (NGVT) Financial Statements
Industry: Chemicals & Allied Products
In fiscal 2025, Ingevity reported revenue of $1.17B, down 17.0% from $1.41B the year before. Net income was -$167.1M (a -14.3% net margin), or -$4.61 per diluted share. Gross margin was 39.5% and operating margin was 35.9%. Operating activities generated $331.2M of cash, leaving $273.5M of free cash flow. At fiscal year end, Ingevity held $1.65B in total assets against $1.62B in total liabilities, including $78.1M of cash and equivalents.
Open the full interactive Ingevity financials → Quarterly statements, key ratios, valuation history and price charts.
Ingevity Key Stats
| Share Price | $70.08 |
|---|---|
| Market Cap | $2.47B |
| Revenue YoY Growth | -17.0% |
| 52-Week Range | $46.20 – $77.87 |
| Shares Outstanding | 34.7 million (basic, 2026 Q2) |
Ingevity Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $1.22B | $1.39B | $1.67B | $1.69B | $1.41B | $1.17B |
| Cost of Goods Sold | $750.6M | $878.7M | $1.10B | $1.22B | $951.7M | $706.1M |
| Gross Profit | $465.5M | $512.8M | $570.1M | $471.9M | $454.7M | $461.5M |
| Operating Income | $397.9M | $422.2M | $452.6M | $396.8M | $369.0M | $418.7M |
| Pre-Tax Income | $235.1M | $162.8M | $269.6M | -$10.1M | -$535.6M | -$142.1M |
| Income Tax | $53.7M | $44.7M | $58.0M | -$4.7M | -$105.3M | $8.2M |
| Net Income | $181.4M | $118.1M | $211.6M | -$5.4M | -$430.3M | -$167.1M |
| Diluted EPS | $4.37 | $2.95 | $5.50 | -$0.15 | -$11.85 | -$4.61 |
Ingevity Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $333.1M | $185.4M | $258.0M | $314.1M |
| Net Income | $43.5M | -$84.6M | $59.8M | $35.3M |
| Diluted EPS | $1.18 | -$2.34 | $1.66 | $1.00 |
Ingevity Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $257.7M | $275.4M | $76.7M | $95.9M | $68.0M | $78.1M |
| Current Assets | $628.7M | $724.9M | $679.0M | $658.6M | $493.2M | $454.2M |
| Total Assets | $2.33B | $2.47B | $2.74B | $2.62B | $2.02B | $1.65B |
| Current Liabilities | $223.4M | $268.9M | $303.5M | $362.9M | $264.1M | $341.3M |
| Total Long-Term Debt | $1.29B | $1.27B | $1.47B | $1.47B | $1.40B | $1.21B |
| Total Liabilities | $1.69B | $1.80B | $2.04B | $1.99B | $1.83B | $1.62B |
| Shareholders' Equity | $642.1M | $673.8M | $698.3M | $631.4M | $195.2M | $29.7M |
Ingevity Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $352.4M | $293.0M | $313.1M | $205.1M | $128.6M | $331.2M |
| Cash From Investing | -$110.6M | -$140.6M | -$553.9M | -$77.3M | -$79.5M | -$57.5M |
| Cash From Financing | -$50.2M | -$133.1M | $48.1M | -$99.9M | -$70.2M | -$252.2M |
| Free Cash Flow | $270.3M | $189.2M | $170.6M | $95.3M | $51.0M | $273.5M |
Figures from Ingevity's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Ingevity financials page for every line item.
Ingevity Company Profile
| Ticker | NGVT |
|---|---|
| Exchange | NYSE |
| Industry | Chemicals & Allied Products |
| Headquarters | North Charleston, South Carolina |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001653477 |
Frequently Asked Questions
What was Ingevity's revenue in fiscal 2025?
Ingevity (NGVT) reported revenue of $1.17B for fiscal 2025.
What is Ingevity's annual revenue history?
Ingevity's annual revenue by fiscal year: 2020: $1.22B; 2021: $1.39B; 2022: $1.67B; 2023: $1.69B; 2024: $1.41B; 2025: $1.17B.
What was Ingevity's net income in fiscal 2025?
Ingevity reported net income of -$167.1M for fiscal 2025.
What was Ingevity's earnings per share (EPS) in fiscal 2025?
Ingevity's diluted EPS was -$4.61 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Ingevity generate in fiscal 2025?
Ingevity generated $273.5M of free cash flow in fiscal 2025.
What was Ingevity's revenue last quarter?
In its most recent reported quarter (2026 Q2), Ingevity reported revenue of $314.1M.
How much debt does Ingevity have?
Ingevity reported $1.21B of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Ingevity are outstanding?
Ingevity reported a weighted average of 34.7 million basic shares outstanding in 2026 Q2.
What is Ingevity's market cap?
Based on its latest closing price, Ingevity (NGVT) has a market capitalization of about $2.47B.
When does Ingevity's fiscal year end?
Ingevity's fiscal year end, as registered with the SEC, is December 31.
Where is Ingevity headquartered?
Ingevity lists its business address in North Charleston, South Carolina in its SEC filings.